312 Covid sub-variant JN.1 cases detected in country, around 47% in Kerala

The INSACOG's data showed 279 Covid cases recorded in the country in December had the presence of JN.1, while 33 such cases were detected in November

covid, corona, coronavirus
The JN.1 sub-variant of the coronavirus was previously classified as a variant of interest (VOI) as part of the BA.2.86 sub-lineages, (Photo: Freepik)
Press Trust of India New Delhi
2 min read Last Updated : Jan 02 2024 | 5:35 PM IST

Don't want to miss the best from Business Standard?

A total of 312 cases of COVID-19 sub-variant JN.1 have been detected in the country so far, with about 47 per cent of them recorded in Kerala, according to the INSACOG's data updated on Tuesday.

Ten states and Union territories have so far detected the presence of the JN.1 sub-variant of the virus.

These states are Kerala (147), Goa (51), Gujarat (34), Maharashtra (26), Tamil Nadu (22), Delhi (16), Karnataka (eight), Rajasthan (five), Telangana (two) and Odisha (one), according to the Indian SARS-CoV-2 Genomics Consortium (INSACOG).

The INSACOG's data showed 279 Covid cases recorded in the country in December had the presence of JN.1, while 33 such cases were detected in November.

The World Health Organisation (WHO) has classified JN.1 as a separate "variant of interest" given its rapidly-increasing spread, but said it poses a "low" global public health risk.

The JN.1 sub-variant of the coronavirus was previously classified as a variant of interest (VOI) as part of the BA.2.86 sub-lineages, the parent lineage that is classified as a VOI, the world body said.

However, in recent weeks, JN.1 cases continued to be reported from multiple countries and its prevalence has rapidly increased globally.

The Centre has asked states and Union territories to maintain a constant vigil amid an uptick in the number of Covid cases and the detection of the JN.1 sub-variant in the country.

India has recorded 573 new coronavirus infections, while the active cases stood at 4,565, according to data released by the Health ministry on Tuesday.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineCoronavirus TestsKerala

First Published: Jan 02 2024 | 5:35 PM IST

Next Story